![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Article |
|---|---|
| Title: | Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas |
| Creators Name: | Jacobs, A., Voges, J., Reszka, R., Lercher, M., Gossmann, A., Kracht, L., Kaestle, C., Wagner, R., Wienhard, K. and Heiss, W.D. |
| Abstract: | In clinical gene-therapy trials for recurrent glioblastomas, transduction of the herpes simplex virus type-1 thymidine kinase (HSV-1-tk) gene with subsequent prodrug activation by ganciclovir was found to be safe, but clinical response was poor. We used positron-emission tomography (PET) with I-124-labelled 2'-fluoro-2'-deoxy-1{beta}-D-arabino-furanosyl-5-iodo-uracil ([ 124I]-FIAU) - a specific marker substrate for gene expression of HSV-1-tk - to identify the location, magnitude, and extent of vector-mediated HSV-1-tk gene expression in a phase I/II clinical trial of gene therapy for recurrent glioblastoma in five patients. The extent of HSV-1-tk gene expression seemed to predict the therapeutic response. The expression of an exogenous gene introduced by gene therapy into patients with gliomas can be monitored non-invasively by PET. |
| Keywords: | Antiviral Agents, Arabinofuranosyluracil, Emission-Computed Tomography, Gene Therapy, Genetic Transduction, Glioblastoma, Human Herpesvirus 1, Local Neoplasm Recurrence, Predictive Value of Tests, Thymidine Kinase, Viral Gene Expression Regulation |
| Source: | Lancet |
| ISSN: | 0140-6736 |
| Publisher: | Lancet |
| Volume: | 358 |
| Number: | 9283 |
| Page Range: | 727-729 |
| Date: | 1 January 2001 |
| Official Publication: | https://doi.org/10.1016/S0140-6736(01)05904-9 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
